Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective
Pharmacoeconomics. 2024 May 7.
doi: 10.1007/s40273-024-01381-z.
Online ahead of print.
1 Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), Maastricht, The Netherlands. Bradley.sugden@mumc.nl.
2 Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), Maastricht, The Netherlands.